UY39482A - Compuestos moduladores del cftr, composiciones y usos de estos - Google Patents

Compuestos moduladores del cftr, composiciones y usos de estos

Info

Publication number
UY39482A
UY39482A UY0001039482A UY39482A UY39482A UY 39482 A UY39482 A UY 39482A UY 0001039482 A UY0001039482 A UY 0001039482A UY 39482 A UY39482 A UY 39482A UY 39482 A UY39482 A UY 39482A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
methods
cftr
cftr modulator
Prior art date
Application number
UY0001039482A
Other languages
English (en)
Inventor
Myongjae Lee
Changmok Oh
Dami Lim
Kyeong-A Kim
Seolhee Lee
Ilji Jeong
Jaeeun Ryu
Jooyun Lee
Yearin Jun
Jinsun Kwon
Te-Ik Sohn
Gunhee Kim
Jungho Kim
Jongmin Yoon
Jin Hee Lee
Hongchul Yoon
Jung Woo Lee
Joontae Park
Kyung Mi An
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of UY39482A publication Critical patent/UY39482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se proporcionan compuestos moduladores de CFTR y composiciones que incluyen dichos compuestos. La presente divulgación también proporciona compuestos inhibidores de PDE4 y composiciones que incluyen dichos compuestos. También se proporcionan métodos para utilizar dichos compuestos y composiciones para modular CFTR, métodos para tratar una enfermedad o trastorno ocular y métodos para tratar indicaciones relacionadas con CFTR. La presente divulgación también proporciona métodos para utilizar dichos compuestos y composiciones para inhibir la PDE4, para tratar una enfermedad o trastorno inflamatorio y para tratar otras indicaciones relacionadas con la PDE4. También se proporcionan métodos de preparación de dichos compuestos y composiciones.
UY0001039482A 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos UY39482A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063104979P 2020-10-23 2020-10-23

Publications (1)

Publication Number Publication Date
UY39482A true UY39482A (es) 2022-05-31

Family

ID=81290147

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039482A UY39482A (es) 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos

Country Status (15)

Country Link
US (1) US11827640B2 (es)
EP (1) EP4232451A1 (es)
JP (1) JP2023547389A (es)
KR (1) KR20230096026A (es)
CN (1) CN116348468A (es)
AR (1) AR123884A1 (es)
AU (1) AU2021363703A1 (es)
CA (1) CA3196061A1 (es)
CL (1) CL2023001139A1 (es)
CO (1) CO2023006647A2 (es)
IL (1) IL302247A (es)
MX (1) MX2023004712A (es)
TW (1) TW202233620A (es)
UY (1) UY39482A (es)
WO (1) WO2022084741A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380835B (zh) * 2022-01-06 2022-12-27 南京桦冠生物技术有限公司 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
DE69130683T2 (de) 1991-04-22 1999-05-06 Otsuka Pharma Co Ltd PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
ES2304511T3 (es) 2002-06-04 2008-10-16 Schering Corporation Compuestos de pirazolo(1,5-a)pirimidina como agentes antivirales.
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
US20070129383A1 (en) 2003-10-17 2007-06-07 Hiroshi Kuramochi Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
US7498434B2 (en) 2004-01-14 2009-03-03 Mallinckrodt Inc Two-phase method for the synthesis of selected pyrazolopyrimidines
CA2568850A1 (en) 2004-08-02 2006-02-16 Schwarz Pharma Ag Indolizine carboxamides and the aza and diaza derivatives thereof
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN103923105B (zh) 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
EP3394083B9 (en) 2015-12-24 2022-04-27 The Regents of the University of California N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis
CN107286156A (zh) 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Also Published As

Publication number Publication date
CA3196061A1 (en) 2022-04-28
AR123884A1 (es) 2023-01-18
CO2023006647A2 (es) 2023-05-29
US20230080486A1 (en) 2023-03-16
KR20230096026A (ko) 2023-06-29
IL302247A (en) 2023-06-01
US11827640B2 (en) 2023-11-28
AU2021363703A1 (en) 2023-06-22
MX2023004712A (es) 2023-05-09
WO2022084741A1 (en) 2022-04-28
CL2023001139A1 (es) 2023-11-17
TW202233620A (zh) 2022-09-01
CN116348468A (zh) 2023-06-27
EP4232451A1 (en) 2023-08-30
JP2023547389A (ja) 2023-11-10

Similar Documents

Publication Publication Date Title
ECSP21086429A (es) Moduladores de la vía integrada del estrés
MX2020004555A (es) Moduladores de la vía de estrés integrada.
EA202091777A1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
MX2020004557A (es) Moduladores de la vía de estrés integrada.
MX2020004551A (es) Moduladores de la vía de estrés integrada.
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
MX2020004538A (es) Moduladores de la vía de estrés integrada.
UY38613A (es) Inhibidores de la proteína tirosina fosfatasa y mètodos de uso de los mismos
CL2021000875A1 (es) Moduladores de profármacos de la vía de estrés integrada
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2020001990A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)
CL2020001991A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1990-20)
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
ECSP23040124A (es) Moduladores de la vía integrada del estrés
ECSP20082339A (es) Moduladores de la expresión de apol1
CO2023006647A2 (es) Compuestos moduladores del cftr, composiciones y usos de estos
WO2020021480A3 (en) Compositions and methods for treating the eye
EA202191342A1 (ru) Модуляторы экспрессии irf5
CO2020008769A2 (es) Moduladores de la expresión dnm2
CL2020000586A1 (es) Moduladores de la expresión de enac.
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
ECSP21042779A (es) Moduladores de la expresión de irf5
MX2023003035A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme.